Merck Stock Slumps as Q4 Profits, 2025 Forecast Fall Short | Global News Avenue

After Merck’s stock fell on Tuesday morning, the soft appearance of the pharmaceutical dealer exceeded the fourth quarter income exceeding the expected fourth quarter.

Merck (Merck (MRKAccording to the visible ALPHA estimation, the revenue of the quarter was US $ 15.62 billion, an increase of 7 % year -on -year to analysts with a year -on -year increase of $ 15.43 billion. The company’s net income was US $ 3.74 billion, that is, $ 1.48 per share, and US $ 1.2 billion in the same period last year, but lower than the expected US $ 3.92 billion analysts.

After adjusting the one -time fee, for example, the cost related to acquisitions, Merck’s adjustment of net income was US $ 4.37 billion, which is estimated to be higher than $ 4.21 billion.

2025 outlook is far from estimated

In 2025, the pharmacist’s expected revenue was between $ 64.1 billion and $ 65.6 billion, and the adjustment of the adjustment per share was between $ 8.88 and $ 9.03 per share. Analysts have higher expectations. The current 2025 consensus is US $ 67.08 billion, and the adjusted earnings per share is $ 9.09.

Most of Merck’s drug combination increased, the decline in sales of Gardasil and Januvia was due to the reduction in demand in certain international regions, and prices in the United States decreased.

Merck shares fell more than 10 % on Tuesday morning.